Flamel Technologies (FLML) Reaches Agreement with FDA on FT218 Phase 3 Trial Design
Go back to Flamel Technologies (FLML) Reaches Agreement with FDA on FT218 Phase 3 Trial Design| Flamel Technologies (NASDAQ: FLML) | Delayed: 10.39 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.39 | 52 Week High | $15.54 | |||
| Open | $19750.79 | 52 Week Low | $7.56 | |||
| Day High | $10.39 | P/E | N/A | |||
| Day Low | $10.39 | EPS | $0.00 | |||
| Volume | 327 | |||||
